Peptide (e.g., Protein, Etc.) Containing Doai Patents (Class 514/1.1)
  • Patent number: 10138282
    Abstract: This disclosure is related to the peptide antagonist of LL-37, an antimicrobial peptide that has multiple functions in both innate and adaptive immune response. Specifically, the identified peptide antagonists of LL-37 provide inhibition to detrimental autoimmune inflammatory response, whereas at the same time retain LL-37's antibacterial activity.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: November 27, 2018
    Assignee: Indiana University Research and Technology Corporation
    Inventors: C. Cheng Kao, Divyendu Singh, Lani Rose San Mateo
  • Patent number: 10138288
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: November 27, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10130682
    Abstract: A method of treating or preventing gonadal or uterine toxicity induced by an agent in a subject is provided. Accordingly there is provided a method comprising administering to a subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is, a method comprising determining gonadal function in a subject; and administering to the subject a therapeutically effective amount of PEDF, thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is a PEDF for use in the treatment or prevention of gonadal toxicity induced by an agent in a subject. Also provided are cell culture, a medium, a kit and method for improving oocyte quality ex-vivo.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 20, 2018
    Assignees: Ramot at Tel-Aviv University Ltd., Mor Research Applications Ltd.
    Inventors: Ruth Shalgi, Dana Chuderland, Hadas Bar-Joseph, Keren Goldberg, Irit Ben-Aharon, Salomon M. Stemmer
  • Patent number: 10130599
    Abstract: A mineral-vitamin complex for osteoporosis includes at least 92 mass % of the mineral-vitamin complex of amino acids and Krebs cycle acids and/or Krebs cycle acid salts, wherein the amino acids include glycine of between 1% and 80% of the mineral-vitamin complex, and wherein the Krebs cycle acids and/or Krebs cycle acid salts are up to 5 mass % of the mineral-vitamin complex; and valine, leucine and isoleucine such that a mass ratio of glycine to a sum of valine+leucine+isoleucine is in a range of 10-1000. Optionally, the valine, leucine and isoleucine are derived from dry milk, any stable dry product derived from milk and/or a mix thereof. Optionally, the following compounds are used as a source of Krebs cycle acid salts: Y-Me-Y.nH2O, where Me—divalent metal, from Ca, Mg, Zn group, Y—anion of an acid participating in Krebs cycle, and n=0-12.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: November 20, 2018
    Inventors: Mikhail Lvovich Uchitel, Roman Anatolievich Trunin, Evgenij Iljich Maevskij
  • Patent number: 10117907
    Abstract: A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC1 receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including ALS, PD, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of ALS, PD, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated PACAP.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: November 6, 2018
    Assignee: Arizona Board of Regents on Behalf of the University of Arizona, a body corporate
    Inventors: Robin Polt, Torsten A E Falk
  • Patent number: 10117915
    Abstract: Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: November 6, 2018
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Donald Bellgrau, Beth Tamburini
  • Patent number: 10111834
    Abstract: A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: October 30, 2018
    Assignee: TDL Innovations, LLC
    Inventor: Glenn W. Laub
  • Patent number: 10105381
    Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: October 23, 2018
    Assignee: CMPD Licensing, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 10105357
    Abstract: A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of an antibiotic drug or a pharmaceutical acceptable salt thereof. The antibiotic drug is selected from the group consisting of an aminoglycoside antibiotic drug, an anti-fungal antibiotic drug, a Cephalosporin antibiotic drug, a ?-propionamide antibiotic drug, a chloramphenicol antibiotic drug, an erythromycin antibiotic drug, a penicillin antibiotic drug, and a tetracycline antibiotic drug.. The cancer is selected from the group consisting of lung cancer, gastrointestinal tract cancer, colorectal cancer, prostate cancer, bladder cancer, cervical cancer, breast cancer, and blood cancer.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: October 23, 2018
    Assignee: LAUNX BIOMEDICAL CO., LTD.
    Inventors: Chiu-Hung Chen, Show-Mei Chuang, Nai-Wan Hsiao, Ruei-Yue Liang, Xiao-Tong Tan
  • Patent number: 10098920
    Abstract: The invention relates to medicine and chemical and pharmaceutical industry, in particular, to methods for producing a complex of biologically active substances exhibiting hypoglycaemic activity of plant material. A method for producing a complex of biologically active substances exhibiting hypoglycaemic activity comprises extracting bean herb with alcohol followed by concentrating and/or drying the extract, wherein the extraction is carried out with 96% alcohol resulting in a first extract and a bean herb residue, wherein the first extract is concentrated resulting in a first solid extract or it is concentrated and dried resulting in a first dry extract and the bean herb residue is extracted with 70% alcohol resulting in a second extract at least a portion of which being concentrated resulting in a second solid extract or being concentrated and dried resulting in a second dry extract.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: October 16, 2018
    Inventor: Akop Surikovych Kutsanyan
  • Patent number: 10092565
    Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminescent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: October 9, 2018
    Assignees: Semorex Technologies Ltd., Ariel-University Research and Development Company Ltd.
    Inventors: Bernard S. Green, Galia Luboshits, Michael A. Firer
  • Patent number: 10092659
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors expressing HER2, wherein the human solid tumor expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2? or 1+ and HER2 FISH negative tumor tissue status.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: October 9, 2018
    Assignees: Synthon Biopharmaceuticals B.V., Yale University
    Inventors: Alessandro Davide Santin, Peter Johannes Goedings
  • Patent number: 10077289
    Abstract: The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 18, 2018
    Assignee: Allergan, Inc.
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, Alex J. Thomas, Michael E. Garst
  • Patent number: 10077319
    Abstract: This application provides anti-PCSK9˜GLP-1 fusions and methods for use.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: September 18, 2018
    Assignees: MedImmune, LLC, MedImmune Limited
    Inventors: Anthony Celeste, Matthieu Chodorge, Andrew Buchanan, Cristina Rondinone, Joseph Grimsby, Peter Ravn, Jonathan Seaman, David Fairman
  • Patent number: 10066228
    Abstract: The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: September 4, 2018
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Peter Linsley, Brian James Leppert, Gunnar J. Hanson
  • Patent number: 10053521
    Abstract: Naphthalimide compounds as used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bone tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 21, 2018
    Assignee: Alumend, LLC
    Inventors: Ronald E. Utecht, Kaia L. Kloster, Millard M. Judy, Kevin J. Vaska, James L. Matthews
  • Patent number: 10053642
    Abstract: There is described a method for producing a biofuel, the method comprising: culturing an Acetobacter lovaniensis bacterium in a growth medium containing phosphate at a level which is more than 1 g/liter, wherein culturing of the bacterium produces the biofuel.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 21, 2018
    Assignee: VERDANT BIOPRODUCTS LIMITED
    Inventor: Irene Finnegan
  • Patent number: 10046060
    Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: August 14, 2018
    Assignee: NoNO INC.
    Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
  • Patent number: 10035847
    Abstract: The invention relates to methods for obtaining antibodies that recognize amyloid protofibrils and antibodies that recognize one or more amyloid protofibrils. Also provided are methods of using the antibodies to prevent or inhibit amyloid disease in a subject, to diagnose amyloid disease in a subject, and to detect amyloid protofibrils in a sample.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: July 31, 2018
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: W. Vallen Graham, Thomas P. Sakmar
  • Patent number: 10034836
    Abstract: The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The GCC agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: July 31, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Stephen Comiskey
  • Patent number: 10023614
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: July 17, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Patent number: 10023555
    Abstract: The present invention discloses novel compounds derived from NSAIDs and pharmaceutically acceptable salts thereof. Other aspects of the invention relate to use of the NSAID derivatives in treating inflammatory diseases and pharmaceutical compositions thereof.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: July 17, 2018
    Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: Khosrow Kashfi, Mitali Chattopadhyay, Ravinder Kodela
  • Patent number: 10010591
    Abstract: The present invention relates to the use of a nucleic acid that comprises a sequence encoding an APOBEC3A protein, in preventing or treating a tumor in a patient.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: July 3, 2018
    Assignee: INVECTYS
    Inventors: Pierre Langlade Demoyen, Anna Kostrzak, Simon Wain-Hobson
  • Patent number: 10011652
    Abstract: The present invention is concerned with immunoglobulin (Ig)-like molecules or fragments thereof for use in treatment, prevention, or prevention of progression of adverse cardiac remodelling and conditions resulting from or relating to myocardial infarction and pressure-overload, such as heart failure, aneurysm formation and remote myocardial fibrosis and for use in improving angiogenesis, preferably after ischemic injury. The invention also provides nucleic acid molecules encoding said Ig-like molecules, vectors comprising same, and host cells comprising same.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: July 3, 2018
    Assignee: UMC UTRECHT HOLDING B.V.
    Inventor: Faith Arslan
  • Patent number: 10004236
    Abstract: The invention provides isolated Brevibacillius laterosporus strains with insecticidal activity against at least one Lepidopteraspecies and at least one Dipteraspecies. In particular the invention provides the isolated B. laterosporus strains NMI No. V12/001946, NMI No. V12/001945 and NMI No. V12/001944. The invention provides compositions comprising one or more strain of the invention. The invention also provides methods of use of one or more strains or compositions of the inventions to control pests, particularly insect pests.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 26, 2018
    Assignee: Lincoln University
    Inventors: Travis Robert Glare, John Graham Hampton, Murray Paul Cox, Damian Alexander Bienkowski
  • Patent number: 10006011
    Abstract: The present invention provides an artificial nuclease comprising a DNA-binding domain and a function domain linked to each other via a polypeptide consisting of 35 to 55 amino acid residues wherein amino acid residues at two sites in a DNA-binding module contained in a DNA-binding domain exhibit a mode of repetition that is different for every four DNA-binding modules; a vector for expressing said artificial nuclease; a vector library for preparing said vector; and a vector set for preparing said vector library.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 26, 2018
    Assignee: Hiroshima University
    Inventors: Takashi Yamamoto, Tetsushi Sakuma, Hiroshi Ochiai, Shinya Matsuura, Tatsuo Miyamoto
  • Patent number: 10000748
    Abstract: The present invention relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to variants of factor IX (F.IX) or activated factor IX (F.IXa), wherein the variant is characterized in that it has increased F.IX clotting activity compared to wildtype. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: June 19, 2018
    Assignee: DRK-BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBH
    Inventors: Jörg Schüttrumpf, Patricia Quade-Lyssy, Peter Milanov, Erhard Seifried
  • Patent number: 9993430
    Abstract: The present invention relates to solid compositions comprising a GLP-1 peptide and a delivery agent, such as SNAC, as well as uses thereof.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: June 12, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Simon Bjerregaard Jensen, Per Sauerberg, Flemming S. Nielsen, Betty L. Pedersen, Erik Skibsted
  • Patent number: 9993575
    Abstract: Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: June 12, 2018
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Wilbur A. Lam, Anton Sidorov, Zhigang Jlang
  • Patent number: 9988629
    Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: June 5, 2018
    Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
  • Patent number: 9987339
    Abstract: The present invention provides a pharmaceutical composition with improved stability, comprising a fusion protein comprising Factor VII (FVII) and transferrin, as an active ingredient, wherein the transferrin is linked to the C-terminus of the FVII; and trehalose or glycine as a bulking agent. The composition can store FVII and a variant thereof stably at room temperature for a long period of time. Thus it can be used as a useful therapeutic agent for patients suffering from hemophilia or congenital FVII deficiency.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: June 5, 2018
    Assignee: TIUMBIO CO., LTD.
    Inventors: Hong-Kee Kim, Ho Chul Shin, Yoon-Jung Lee, Ho Soon Lee, Ji-Hye Lee, Seok-chan Kang, Hun-Taek Kim
  • Patent number: 9980931
    Abstract: A prophylactic or therapeutic agent is provided for depression (including each subtype according to DSM-IV of depression) or anxiety by increasing the levels of serotonin in the brain includes administration of glycyl-glutamine or cyclo glycyl-glutamine, a derivative that could cross the blood-brain barrier and could be used in peripheral applications.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: May 29, 2018
    Assignees: Uludag Universitesi Teknoloji Transfer Ofisi Ticaret Ve Sanayi Anonim Suirketi
    Inventors: Mustafa Sertaç Yilmaz, Sinan Çavun
  • Patent number: 9981012
    Abstract: The effects of hepcidin treatment on mitigating renal ischemiareperfusion injury (IRI) and acute kidney injury (AKI) by decreasing iron availability and ROS-mediated cell death were tested. C57Bl/6 (WT) and hepcidin knock out (Hamp?/?) mice were treated with saline or 50 ?g of hepcidin i.p. prior to bilateral renal IRI. Renal function, injury markers, histopathology, and inflammation were examined after 24 hours of reperfusion. In WT mice, IRI induced increases in serum and kidney non-heme iron levels, but hepcidin treatment induced sequestration of iron in the spleen and liver and prevented IRI-associated increases in serum and kidney non-theme iron. Kidney function was significantly better in hepcidin-treated mice, accompanied by less acute tubular necrosis and reduced infiltration of immune cells. Hepcidin treatment decreased kidney ferroportin expression and induced the expression of cytoprotectant, H-Ferritin, and was associated with less ROS and tubular epithelial apoptosis.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: May 29, 2018
    Assignee: University of Virginia Patent Foundation
    Inventor: Sundararaman Swaminathan
  • Patent number: 9968688
    Abstract: A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: May 15, 2018
    Assignee: Verily Life Sciences LLC
    Inventors: Alberto Clemente Vitari, Joshua Simon Klein, Jerrod Joseph Schwartz, Andrew Homyk, Marija Pavlovic
  • Patent number: 9968665
    Abstract: Described herein are multilayer films that include modified polypeptide epitopes from Plasmodium falciparum, specifically a modified T* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes the modified T* polypeptide epitope from a Plasmodium protozoan.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: May 15, 2018
    Assignee: ARTIFICIAL CELL TECHNOLOGIES, INC.
    Inventors: James Gorham Boyd, Thomas J. Powell
  • Patent number: 9956297
    Abstract: Disclosed are proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Also disclosed are related pharmaceutical compositions, and methods of using the inhibitors and prodrugs and compositions thereof, for example, in treating cancer or other cell proliferative diseases. In vitro and in vivo methods of quantifying the expression of FAP in a biopsy sample and a mammal, respectively, are also disclosed.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 1, 2018
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-sen Lai, Sarah E. Poplawski
  • Patent number: 9956711
    Abstract: This invention describes a modified electrospinning method for making uniformly patterned and porous nanofibrous scaffolds that can be utilized in a variety of applications. While traditional electrospinning method uses a foil collector that generates compact layers of nanofibrous structures, resulting on the superficial cell growth and differentiation, the present method comprises adopting additional patterned film(s) on top of the conventional collector to make a patterned porous structure of nanofibrous scaffolds that are capable of supporting cell growth. For example, the method uses a double layered collector composed of a water soluble stabilizer film mounted on a foil to make a uniformly patterned and porous nanofibrous membrane sheets, which enhance both cell growth and attachment.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: May 1, 2018
    Assignee: CAS IN BIO
    Inventors: Dong Jin Lim, Jeremy Benton Vines
  • Patent number: 9956435
    Abstract: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: May 1, 2018
    Assignee: REVANCE THERAPEUTICS, INC.
    Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
  • Patent number: 9943624
    Abstract: The invention provides novel surface coatings having surface polymer brushes with zwitterionic and antibiotics-conjugated side chains and synergistic anti-fouling and bactericidal properties. The surface coatings may be prepared using highly efficient surface-initiated “living” polymerization. The design of the surface polymer brushes are highly modular, allowing independent tuning of the anti-fouling and bactericidal properties, e.g., by varying the chemical nature of the zwitterionic motif and the antibiotic agent, the chemistry through which the antibiotic agent is conjugated to the polymer side chains, the molecular weight of the polymer brushes (e.g., thickness of coating and density of respective functional motifs), and the spatial arrangement of the respective functional motifs (e.g., homopolymers, block copolymers, random copolymers) to achieve optimal and sustained anti-infection outcome for a given application.
    Type: Grant
    Filed: November 24, 2013
    Date of Patent: April 17, 2018
    Assignee: University of Massachusetts
    Inventors: Jie Song, Pingsheng Liu, David C. Ayers
  • Patent number: 9944926
    Abstract: The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 17, 2018
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Linsley, Brian James Leppert
  • Patent number: 9943333
    Abstract: The present invention relates to an agent for activating mammalian sperm and a method for activating sperm by use of the activating agent. More specifically, the present invention relates to a sperm activating agent containing endo-?-galactosidase and/or FGF, which accelerate motility of mammalian sperm, for use in in-vitro fertilization and artificial insemination by husband and a sperm activating method by adding endo-?-galactosidase and/or FGF.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: April 17, 2018
    Assignees: NATIONAL UNIVERSITY CORPORATION, HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Kazuhiro Sugihara, Michiko Fukuda
  • Patent number: 9938445
    Abstract: The present disclosure discloses a comb polymer or a salt thereof, wherein the structural formula of the comb polymer containing the following constitutional units. When the comb polymer provided in the present disclosure is used in a water-based drilling fluid as a filtration control agent, it can eliminate the defects of conventional filtration control agents which would be subject to ineffectiveness under high temperature and high salinity conditions. The comb polymer has high temperature and salt resistance, and can be produced through simple processes at comparatively low costs. When the comb polymer provided by the present disclosure is used as a filtration control agent, even being added into the drilling fluid at a comparatively low amount, it can still present rather good effects in lowering the amount of filter loss.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 10, 2018
    Assignees: Sinopec Oilfield Service Corporation, Drilling Technology Research Institute of Sinopec
    Inventors: Gongrang Li, Qiang Lan, Peng Zhang, Chengsheng Zheng, Yunbo Xu, Xueqin Wu, Zuohui Li, Yanjun Zhou, Hong Zhang
  • Patent number: 9937257
    Abstract: The present invention relates to a method for providing an embedded mammalian cell, comprising the steps of providing an alginate sulfate in aqueous solution; reacting the alginate sulfate to form a hydrogel in a gelation step, providing a precursor cell, and embedding the precursor cell in the sulfated alginate hydrogel in an embedding step, thus yielding an sulfated alginate hydrogel embedded cell. The invention further relates to sulfated alginate hydrogels, and cellular grafts comprising a mammalian cell embedded in sulfated alginate hydrogel.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: April 10, 2018
    Assignee: ETH Zurich
    Inventors: Marcy Zenobi-Wong, Gemma Palazzolo, Rami Mhanna, Jana Becher, Stefanie Moller, Matthias Schnabelrauch
  • Patent number: 9931370
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of metabolic conditions. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: April 3, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9925241
    Abstract: The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1c-binding protein, a ?-Klotho-binding protein and a FGFR1c-binding protein, a C-terminal region from FGF19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: March 27, 2018
    Assignee: Salk Institute for Biological Studies
    Inventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Ruth T. Yu
  • Patent number: 9919029
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections. In particular, the present invention relates to a Toll-like receptor (TLR) agonist for use in a method for the treatment of a bacterial infection in a subject in need thereof wherein the TLR agonist is administered to the subject in combination with at least one antibiotic.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: March 20, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Droit et de la Sante de Lille 2, Centre National de la Recherche Scientifique (CNRS), Institut Pasteur de Lille, Universite de Lille 1 Sciences et Technologies, ETH Zurich, Universidad de la Republica
    Inventors: Wolf-Dietrich Hardt, Patrick Kaiser, Jean-Claude Sirard, Christophe Carnoy, Delphine Fougeron, Jose Alejandro Chabalgoity, Natalia Munoz
  • Patent number: 9920304
    Abstract: A peptide for synthesizing silica and use thereof are provided. The peptide for synthesizing silica can polymerize silica from a silica precursor in an aqueous solution having conditions of normal temperature, normal pressure and near-neutral weak base. The peptide for synthesizing silica can form a self-assembled structure during silica synthesis, and thus can be used as various biomaterials such as a silica-based protein immobilizer, a biosensor, and a drug delivery system.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 20, 2018
    Assignee: Korea University Research and Business Foundation, Sejong Campus
    Inventors: Seung Pil Pack, Mi Ran Ki
  • Patent number: 9914764
    Abstract: This disclosure relates to variant Factor VIII polypeptides comprising an amino acid substitution at one or more positions within one or both of the thrombin cleavage site and the activation loop. In certain embodiments, the variant Factor VIII polypeptide comprises one or more amino acid substitutions within both the thrombin cleavage site and the activation loop. In further embodiments, the variant factor VIII polypeptide further comprises one or more amino acid substitutions within the A1-A2 domain interface and the A2-A3 domain interface. The present disclosure further relates to methods of producing and/or using such variant Factor VIII polypeptides; nucleic acids encoding the polypeptides; vectors and/or recombinant cells, tissues, or organisms containing such nucleic acids; and kits and pharmaceutical compositions containing such polypeptides and/or nucleic acids.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 13, 2018
    Assignee: BAYER HEALTHCARE, LLC
    Inventors: Uwe Gritzan, Peter Kretschmer, Lilley Leong, Chandra Patel
  • Patent number: 9902957
    Abstract: Co-oligomer compounds, complexes of the same with polyanions, such as siRNAs, and methods for using the same are provided. the delivery of polynucleotides, into a cell. The subject co-oligomers include at least a liphopilic monomer and at least a hydrophilic monomer (e.g., a guanidinium containing monomer). In some embodiments, the co-oligomer compounds are capable of complexing a siRNA of interest, thereby increasing the cell permeability of the siRNA, prior to release of the siRNA into the cell. In some embodiments, the subject method is a method of delivery a siRNA into a cell. In some embodiments, the subject method is a method of reducing expression of a protein target of a siRNA of interest. The subject co-oligomer/siRNA complexes may be formulated and administered to a subject to treat a condition resulting from expression of a protein target of the siRNA of interest.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: February 27, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Christina Barnes Cooley, Erika Geihe Stanzl, Robert M. Waymouth, Paul Wender
  • Patent number: 9890198
    Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 13, 2018
    Assignee: S&T Global Inc.
    Inventors: Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang